Skip to content
← All treatment topics

TREATMENT READING

Agnostic Cancer Therapies (PDQ®)

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

Health professional

Introduction

Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

The U.S. Food and Drug Administration (FDA) has approved both gene- and immune-targeted drugs for tissue-agnostic, genomic biomarker–based indications in patients with lethal solid tumors and blood cancers. High response rates were the basis for these approvals.[1]

Sources: 1

Precision medicine has rapidly changed the oncology field. Next-generation sequencing can identify patients with specific gene alterations or immune markers for which there are targeted therapies. Biomarker-based treatments are increasingly emerging, and the FDA has approved the following tissue-agnostic therapies:[1,2]

Sources: 1 · 2

Pembrolizumab.

Dostarlimab.

Entrectinib.

Larotrectinib.

Repotrectinib.

Dabrafenib in combination with trametinib.

Selpercatinib.

Pemigatinib.

Trastuzumab deruxtecan.

Precision medicine is constantly evolving, and improved diagnostic tools allow for more comprehensive genomic definition of the tumor. Tissue-agnostic targeted therapies are a promising treatment strategy tailored to the specific tumor genomic profile, leading to improved patient survival outcomes.

The list of drugs approved for tumors with genomic alterations will likely expand as understanding of the science driving these cancers continues to advance. As oncology drug development continues to move rapidly, the location where the cancer originated will become less critical.

Companion tests can determine the presence of specific genomic alterations or immune markers. These tests may have been approved by the FDA as part of the agnostic drug approval. Most insurance companies have not required these specific tests before covering the prescribed medications.

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional

Microsatellite Instability–High or Mismatch Repair–Deficient Solid Tumors

Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Health professional · Microsatellite Instability–High or Mismatch Repair–Deficient Solid Tumors

Pembrolizumab

Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Indication. Pembrolizumab is indicated for adult and pediatric patients with unresectable or metastatic, microsatellite instability–high (MSI-H)/microsatellite unstable or mismatch repair–deficient (dMMR) solid tumors whose disease progressed after prior treatment and who have no satisfactory alternative treatment options. The MSI-H phenotype is associated with germline defects in the MLH1, MSH2, MSH6, and PMS2 genes and is the primary phenotype observed in tumors from patients with hereditary nonpolyposis colorectal cancer or Lynch syndrome. Patients can also have the MSI-H phenotype because one of these genes was silenced via DNA methylation. Molecular genetic tests look for microsatellite instability in the tumor tissue, and immunohistochemistry tests for the loss of mismatch repair proteins. For more information, see the Immunotherapy section in Colon Cancer Treatment.

Sources: Immunotherapy

Evidence. The U.S. Food and Drug Administration (FDA) approval was based on data from the following five uncontrolled, multicohort, multicenter, single-arm clinical trials that included 149 patients with MSI-H or dMMR cancers:[1][Level of evidence C3]

Sources: 1 · Level of evidence C3

KEYNOTE-016 (NCT01876511) (median follow-up, 5.3 months).[2]

Sources: KEYNOTE-016 · 2

KEYNOTE-164 (NCT02460198) (median follow-up, 31.3 months).[3]

Sources: KEYNOTE-164 · 3

KEYNOTE-012 (NCT01848834) (median follow-up, 9 months).[4]

Sources: KEYNOTE-012 · 4

KEYNOTE-028 (NCT02054806) (median follow-up, 9.8 months).[5]

Sources: KEYNOTE-028 · 5

KEYNOTE-158 (NCT02628067) (median follow-up, 13.4 months).[6]

Sources: KEYNOTE-158 · 6

These trials included 90 patients with colorectal cancer and 59 patients with other cancers who were diagnosed with one of 14 other cancer types. Patients received either 200 mg of pembrolizumab every 3 weeks or 10 mg/kg of pembrolizumab every 2 weeks.

Efficacy. The major efficacy outcome measures were objective response rate, assessed by blinded independent central radiologist review according to RECIST 1.1, and response duration. The pooled objective response rate was 39.6%. A total of 11 patients (7.4%) had a complete response and 48 patients (32.2%) had a partial response. The objective response rate was 36% in patients with colorectal cancer, and 46% in patients with other cancers (95% confidence interval [CI], 33%–59%).[7,8] Responses lasted 6 months or longer for 78% of patients who responded to pembrolizumab.[1]

Sources: 7 · 8 · 1

Identification of biomarker. For most patients (135 of 149), tumor status was prospectively determined using local laboratory-developed, investigational polymerase chain reaction (PCR) (for MSI-H) or immunohistochemistry (for dMMR).[9] For 14 of the 149 patients, MSI-H status was determined in a retrospective assessment of tumor samples from 415 patients using a central laboratory-developed PCR test.

Sources: 9

Health professional · Microsatellite Instability–High or Mismatch Repair–Deficient Solid Tumors

Dostarlimab

Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Indication. Dostarlimab is indicated for adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA-approved test, whose disease progressed during or after prior treatment and who have no satisfactory alternative treatment options. This indication is not approved in the pediatric population.

Evidence. GARNET (NCT02715284) was a nonrandomized, multicenter, open-label, multicohort trial that evaluated the efficacy of dostarlimab.[10] The expansion cohorts were as follows:[11-14][Level of evidence C3]

Sources: GARNET · 10 · 11 · 14 · Level of evidence C3

dMMR/MSI-H endometrial cancers.

Mismatch repair–proficient or microsatellite stable endometrial cancers.

Non-small cell lung cancers.

Non-endometrial dMMR/MSI-H and POLE-mutated cancers.

High-grade serous, endometrioid, or clear cell ovarian, fallopian tube, or primary peritoneal cancer without BRCA variants.

Efficacy. The efficacy population consisted of 209 patients with dMMR recurrent or advanced solid tumors whose disease progressed after systemic therapy and who had no satisfactory alternative treatment options. The objective response rate was 41.6% (95% CI, 34.9%–48.6%), with a 9.1% complete response rate and a 32.5% partial response rate. The median follow-up was 27.7 months.[10]

Sources: 10

Identification of biomarker. The VENTANA MMR RxDx Panel is a companion diagnostic device to select patients with dMMR solid tumors for treatment with dostarlimab.

Health professional

Tumor Mutational Burden–High (≥10 Mutations/Megabase) Solid Tumors

Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Health professional · Tumor Mutational Burden–High (≥10 Mutations/Megabase) Solid Tumors

Pembrolizumab

Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Indication. Pembrolizumab is indicated for adult and pediatric patients with unresectable or metastatic tumor mutational burden–high (TMB-H) solid tumors, whose disease progressed after prior treatment and who have no satisfactory alternative treatment options. TMB-H is defined as ≥10 mutations/megabase (mut/Mb), as determined by a U.S. Food and Drug Administration (FDA)-approved test.

Evidence. FDA approval was based on a retrospective analysis of 10 cohorts of patients with various previously treated unresectable or metastatic TMB-H solid tumors enrolled in KEYNOTE-158 (NCT02628067), a multicenter, nonrandomized, open-label trial. Patients received 200 mg of pembrolizumab intravenously every 3 weeks until unacceptable toxicity or documented disease progression.[1,2][Level of evidence C3]

Sources: KEYNOTE-158 · 1 · 2 · Level of evidence C3

Efficacy. A total of 102 patients (13%) had TMB-H tumors (defined as TMB ≥10 mut/Mb). The objective response rate for these patients was 29% (95% confidence interval, 21%–39%), with a 4% complete response rate and 25% partial response rate.[1] The median follow-up was 13.4 months.[2]

Sources: 1 · 2

Identification of biomarker. The FoundationOne CDx assay is a companion diagnostic test for pembrolizumab.

Health professional

NTRK Gene Fusion–Positive Solid Tumors

Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Health professional · NTRK Gene Fusion–Positive Solid Tumors

Entrectinib

Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Indication. Entrectinib is indicated for adult and pediatric patients with solid tumors and an NTRK gene fusion without a known acquired resistance variant; with disease that is metastatic or where surgical resection is likely to result in severe morbidity; and who have disease progression after treatment or have no satisfactory standard therapy.

Evidence. Five multicenter single-arm clinical trials evaluated the efficacy of entrectinib in patients with NTRK-positive tumors. Three of these trials evaluated a total of 54 adult patients who received entrectinib at various doses and schedules. Two of these trials evaluated a total of 33 pediatric patients.[1,2][Level of evidence C3]

Sources: 1 · 2 · Level of evidence C3

ALKA-372-001; adult patients.

Sources: ALKA-372-001

STARTRK-1 (NCT02097810); adult patients.

Sources: STARTRK-1

STARTRK-2 (NCT02568267); adult patients.

Sources: STARTRK-2

STARTRK-NG (NCT02650401); pediatric patients.

Sources: STARTRK-NG

TAPISTRY (NCT04589845); pediatric patients.

Sources: TAPISTRY

Efficacy. Among the 54 adult patients, the overall response rate, as determined by independent review, was 57% (95% confidence interval [CI], 43%–71%). The median follow-up was 15 months.[1] Among the 33 pediatric patients, the objective response rate was 70% (95% CI, 51%–84%), and the median duration of response was 25.4 months (95% CI, 14.3–not evaluable). The median follow-up was not defined.[2]

Sources: 1 · 2

Identification of biomarker. Identification of positive NTRK gene fusion status was determined at local laboratories or a central laboratory using nucleic acid-based tests prior to enrollment. Not all NTRK variants are gene fusions. Entrectinib has not shown clinical efficacy in patients with nonfusion NTRK variants..

Health professional · NTRK Gene Fusion–Positive Solid Tumors

Larotrectinib

Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Indication. Larotrectinib is indicated for adult and pediatric patients with solid tumors and an NTRK gene fusion without a known acquired resistance variant; with disease that is metastatic or where surgical resection is likely to result in severe morbidity; and who have disease progression after treatment and have no satisfactory alternative treatment options.

Evidence. U.S. Food and Drug Administration (FDA) approval was based on data from three multicenter, open-label, single-arm clinical trials: LOXO-TRK-14001 (NCT02122913), SCOUT (NCT02637687), and NAVIGATE (NCT02576431).[3,4][Level of evidence C3]

Sources: LOXO-TRK-14001 · SCOUT · NAVIGATE · 3 · 4 · Level of evidence C3

Efficacy. Among 55 patients with unresectable or metastatic solid tumors harboring an NTRK gene fusion enrolled across the three trials, the overall response rate was 75% (95% CI, 61%–85%). The complete response rate was 22%, and the partial response rate was 53%. The median follow-up was 8.3 months.[3,5]

Sources: 3 · 5

Identification of biomarker. NTRK gene fusion status was prospectively determined at local laboratories using next-generation sequencing (NGS) or fluorescence in situ hybridization (FISH). Not all NTRK variants are gene fusions. Entrectinib has not shown clinical efficacy in patients with nonfusion NTRK variants..

Health professional · NTRK Gene Fusion–Positive Solid Tumors

Repotrectinib

Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Indication. Repotrectinib is indicated for adult and pediatric patients with an NTRK gene fusion and solid tumors that are locally advanced or metastatic for which surgical resection may cause severe morbidity.

Evidence. FDA approval was based on data from TRIDENT-1 (NCT03093116), a multicenter, single-arm, open-label, multicohort trial.[6-8][Level of evidence C3]

Sources: TRIDENT-1 · 6 · 8 · Level of evidence C3

Efficacy. In 88 adult patients with locally advanced or metastatic NTRK gene fusion–positive solid tumors, the overall response rate was 58% (95% CI, 41%–73%) for patients who had not received prior NTRK tyrosine kinase inhibitors (TKIs) (n = 40) and 50% (95% CI, 35%–65%) for patients who had previously received NTRK TKIs (n = 48). The median duration of response was not estimable in the TKI-naïve group and was 9.9 months (95% CI, 7.4–13.0) in the TKI-pretreated group. The median follow-up was 24.0 months.[6,8]

Sources: 6 · 8

Identification of biomarker. NTRK gene fusion status was prospectively determined at local laboratories using NGS, Sanger sequencing, reverse transcription–polymerase chain reaction, or FISH. Not all NTRK variants are gene fusions. Repotrectinib has not shown clinical efficacy in patients with nonfusion NTRK variants.

Health professional

BRAF V600E Variant–Positive Solid Tumors

Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Health professional · BRAF V600E Variant–Positive Solid Tumors

Dabrafenib in Combination With Trametinib

Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Indication. The combination of dabrafenib and trametinib is indicated for adult and pediatric patients aged 6 years or older with unresectable or metastatic solid tumors and a BRAF V600E variant. Patients must have progressive disease after prior treatment and have no satisfactory alternative treatment options. Dabrafenib in combination with trametinib is not indicated for patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition.

Evidence. The U.S. Food and Drug Administration approval was based on data from the following populations:[1-5][Level of evidence C3]

Sources: 1 · 5 · Level of evidence C3

Two open-label multiple cohort trials included 131 adult patients: BRF117019 (NCT02034110) (median follow-up, 47 weeks), and NCI-MATCH (NCT02465060) protocol H (median follow-up, 23.0 months).[1-3]

Sources: BRF117019 · NCI-MATCH · 1 · 3

One trial included 36 pediatric patients: CTMT212X2101 (NCT02124772) (median follow-up, not defined).[4]

Sources: CTMT212X2101 · 4

The approval was also supported by results from COMBI-d (NCT01072175), COMBI-v (NCT01597908), and BRF113928 (NCT01336634).[6]

Sources: COMBI-d · COMBI-v · BRF113928 · 6

Efficacy. For the 131 adult patients, the overall response rate was 41% (95% confidence interval [CI], 33%–50%). For the 36 pediatric patients, the overall response rate was 25% (95% CI, 12%–42%).[5]

Sources: 5

Identification of biomarker. Biomarker status was determined at a Clinical Laboratory Improvement Amendments (CLIA) or CLIA-equivalent laboratory.

Health professional

RET Gene Fusion–Positive Solid Tumors

Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Health professional · RET Gene Fusion–Positive Solid Tumors

Selpercatinib

Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Indication. Selpercatinib is indicated for adult patients with locally advanced or metastatic solid tumors with a RET gene fusion whose disease meets either of the following criteria: disease progressed during or after prior systemic treatment, or disease with no satisfactory alternative treatment options. This indication is not approved for the pediatric population.

Evidence. Forty-one patients with RET gene fusion–positive tumors (other than non-small cell lung cancer [NSCLC] and thyroid cancer) with disease progression during or after prior systemic treatment or who had no satisfactory alternative treatment options were evaluated in the multicenter, open-label, multicohort LIBRETTO-001 trial (NCT03157128).[1,2][Level of evidence C3]

Sources: LIBRETTO-001 · 1 · 2 · Level of evidence C3

Efficacy. For the 41 evaluable patients with cancers other than NSCLC or thyroid cancer, the objective response rate was 44% (95% confidence interval, 28%–60%). A total of 16 patients had a partial response and 2 patients had a complete response, with a median follow-up of 14.9 months.[1,2]

Sources: 1 · 2

Identification of biomarker. Clinical Laboratory Improvement Amendments (CLIA) or CLIA-equivalent locally obtained molecular testing was performed at a certified laboratory, with the use of either next-generation sequencing, fluorescence in situ hybridization, or polymerase chain reaction assay.

Health professional

FGFR1-Rearranged Myeloid/Lymphoid Neoplasms

Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Health professional · FGFR1-Rearranged Myeloid/Lymphoid Neoplasms

Pemigatinib

Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Indication. Pemigatinib is indicated for adult patients with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with an FGFR1 rearrangement. This indication is not approved for the pediatric population.

Evidence. Twenty-eight patients with relapsed or refractory MLNs with FGFR1 rearrangement were evaluated in the multicenter open-label, single-arm FIGHT-203 trial (NCT03011372). Eligible patients were either not candidates for, or had relapsed disease after, allogeneic hematopoietic stem cell transplant or a disease-modifying therapy (e.g., chemotherapy).[1,2][Level of evidence C3]

Sources: FIGHT-203 · 1 · 2 · Level of evidence C3

Efficacy. For all 28 patients (including three patients without evidence of morphologic disease), the complete cytogenetic response rate was 79% (95% confidence interval [CI], 59%–92%). Among the 18 patients with chronic phase disease in the marrow with or without extramedullary disease (EMD), 14 achieved a complete response (78%; 95% CI, 52%–94%). Among the four patients with blast-phase disease in the marrow with or without EMD, two achieved a complete response (duration, 1+ and 94 days). For the three patients with EMD only, one achieved a complete response (duration, 64+ days) with a median follow-up of 25.3 months.[1,2]

Sources: 1 · 2

Identification of biomarker. Biomarker identification was performed using local cytogenetics and both local and central fluorescence in situ hybridization results.

Health professional

HER2–Expressing Solid Tumors

Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Health professional · HER2–Expressing Solid Tumors

Trastuzumab Deruxtecan (T-DXd)

Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Indication. T-DXd is indicated for adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.[1] This indication is not approved in the pediatric population.

Sources: 1

Evidence. One hundred ninety-two adult patients with previously treated unresectable or metastatic HER2-positive (IHC 3+) solid tumors were enrolled in one of the following three multicenter trials:[2-4][Level of evidence C3]

Sources: 2 · 4 · Level of evidence C3

DESTINY-PanTumor02 (NCT04482309).[2]

Sources: DESTINY-PanTumor02 · 2

DESTINY-Lung01 (NCT03505710).[3]

Sources: DESTINY-Lung01 · 3

DESTINY-CRC02 (NCT04744831).[4]

Sources: DESTINY-CRC02 · 4

Efficacy. The objective response rates were as follows:

51.4% (95% confidence interval [CI], 41.7%–61.0%) for patients in the DESTINY-PanTumor02 trial.

52.9% (95% CI, 27.8%–77.0%) for patients in the DESTINY-Lung01 trial.

46.9% (95% CI, 34.3%–59.8%) for patients in the DESTINY-CRC02 trial.

Identification of biomarker. Eligible patients had centrally confirmed HER2 positivity (IHC 3+).

Health professional

Potential Emerging Agnostic Targets Not Yet Approved by the U.S. Food and Drug Administration

Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Health professional · Potential Emerging Agnostic Targets Not Yet Approved by the U.S. Food and Drug Administration

Tumor Mutational Burden–High (TMB-H) (≥16 Mutations/Megabase [mut/Mb]) Solid Tumors

Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Health professional · Potential Emerging Agnostic Targets Not Yet Approved by the U.S. Food and Drug Administration / Tumor Mutational Burden–High (TMB-H) (≥16 Mutations/Megabase [mut/Mb]) Solid Tumors

Atezolizumab

Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Target and mechanism. Atezolizumab blocks the interaction of programmed death-ligand 1 (PD-L1) with programmed cell death 1 (PD-1) and CD80 receptors (B7-1Rs).

Current approvals. Atezolizumab is approved for non-small cell lung cancer,[1-5] small-cell lung cancer,[6] hepatocellular carcinoma,[7] melanoma,[8] and alveolar soft part sarcoma.[9]

Sources: 1 · 5 · 6 · 7 · 8 · 9

Supporting study. Atezolizumab was evaluated in a phase IIa, multibasket, MyPathway study. The preplanned primary end point was objective response rate in patients with TMB-H (≥16 mut/Mb) tumors by FoundationOne TMB testing.[10]

Sources: 10

Study population. This study included 120 patients with advanced solid tumors with TMB ≥10 mut/Mb by any Clinical Laboratory Improvement Amendments (CLIA)-certified assay. Among patients with local or central FoundationOne TMB testing results, 42 had TMB ≥16 mut/Mb tumors, comprising the primary efficacy population, and 49 had TMB ≥10 and <16 mut/Mb tumors, of whom 48 were efficacy evaluable.[10]

Sources: 10

Efficacy. In the primary analysis population of 42 patients with TMB ≥16 mut/Mb tumors, the confirmed objective response rate was 38.1% (95% confidence interval [CI], 23.6%–54.4%) and the disease-control rate (the best response of complete response, partial response, or stable disease >4 months) was 61.9% (95% CI, 45.6%–76.4%), with a median follow-up of 9.9 months.[10][Level of evidence C3]

Sources: 10 · Level of evidence C3

Studies

Vaccine Therapy in Treating Patients With Advanced Cancer

NCT00004881 · COMPLETED · phase1

Unspecified Adult Solid Tumor, Protocol Specific

ClinicalTrials.gov record

Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors

NCT00070473 · COMPLETED · phase1

Unspecified Childhood Solid Tumor, Protocol Specific

ClinicalTrials.gov record

A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy

NCT00468546 · COMPLETED · phase3

Rheumatoid Arthritis

ClinicalTrials.gov record

Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors

NCT00622414 · COMPLETED · phase1

Unspecified Childhood Solid Tumor, Protocol Specific

ClinicalTrials.gov record

Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

NCT01072175 · COMPLETED · phase2

Cancer

ClinicalTrials.gov record

Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis

NCT01437787 · TERMINATED · phase3

Hematopoietic Neoplasm

ClinicalTrials.gov record

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

NCT01597908 · COMPLETED · phase3

Melanoma

ClinicalTrials.gov record

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)

NCT01848834 · COMPLETED · phase1

Cancer, Solid Tumor

ClinicalTrials.gov record

Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)

NCT01876511 · COMPLETED · phase2

MSI Positive Colorectal Cancer, MSI Negative Colorectal Cancer, MSI Positive Non-Colorectal Cancers

ClinicalTrials.gov record

Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors

NCT01956669 · COMPLETED · phase2

Solid Tumours

ClinicalTrials.gov record

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

NCT02034110 · COMPLETED · phase2

Cancer

ClinicalTrials.gov record

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)

NCT02054806 · COMPLETED · phase1

Solid Tumor

ClinicalTrials.gov record

A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

NCT02091999 · COMPLETED · phase1

Metastatic Urothelial Cancer and Other Malignant Solid Tumors

ClinicalTrials.gov record

A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

NCT02122913 · COMPLETED · phase1

Solid Tumors Harboring NTRK Fusion

ClinicalTrials.gov record

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

NCT02124772 · COMPLETED · phase1, phase2

Cancer

ClinicalTrials.gov record

VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors

NCT02164838 · COMPLETED · phase1

Refractory or Recurrent Solid Tumors, Excluding CNS Tumors

ClinicalTrials.gov record

This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas

NCT02171260 · COMPLETED · phase1

Pediatrics, Solid Tumors

ClinicalTrials.gov record

Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)

NCT02460198 · COMPLETED · phase2

Colorectal Carcinoma

ClinicalTrials.gov record

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060 · ACTIVE NOT RECRUITING · phase2

Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma,...

ClinicalTrials.gov record

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors

NCT02541604 · TERMINATED · phase1, phase2

Solid Tumor

ClinicalTrials.gov record

A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

NCT02564198 · COMPLETED · phase1

Pediatric Solid Tumor, Refractory Tumor, Recurrent Tumor, CNS Malignancies

ClinicalTrials.gov record

Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors

NCT02564900 · COMPLETED · phase1

Advanced Solid Tumors

ClinicalTrials.gov record

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

NCT02576431 · COMPLETED · phase2

Solid Tumors Harboring NTRK Fusion

ClinicalTrials.gov record

A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children

NCT02637687 · ACTIVE NOT RECRUITING · phase1, phase2

Solid Tumors Harboring NTRK Fusion

ClinicalTrials.gov record

Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors

NCT02639546 · COMPLETED · phase1, phase2

Solid Tumors

ClinicalTrials.gov record

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

NCT02650401 · ACTIVE NOT RECRUITING · phase1, phase2

Solid Tumors, CNS Tumors

ClinicalTrials.gov record

Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

NCT02715284 · ACTIVE NOT RECRUITING · phase1

Neoplasms

ClinicalTrials.gov record

An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer

NCT02743494 · COMPLETED · phase3

Advanced Cancer

ClinicalTrials.gov record

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

NCT03011372 · COMPLETED · phase2

MPN (Myeloproliferative Neoplasms)

ClinicalTrials.gov record

Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors

NCT03352531 · COMPLETED · phase1

Advanced Cancer

ClinicalTrials.gov record

Durvalumab and Tremelimumab for Pediatric Malignancies

NCT03837899 · ACTIVE NOT RECRUITING · phase1, phase2

Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies

ClinicalTrials.gov record

A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies

NCT03913741 · COMPLETED · phase1, phase2

Solid Tumor

ClinicalTrials.gov record

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

NCT04185883 · ACTIVE NOT RECRUITING · phase1

Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation

ClinicalTrials.gov record

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

NCT04238819 · COMPLETED · phase1, phase2

Relapsed Solid Tumor, Refractory Solid Tumor

ClinicalTrials.gov record

AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).

NCT04380753 · COMPLETED · phase1

Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation

ClinicalTrials.gov record

A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)

NCT04447755 · COMPLETED · phase2

Relapsed or Refractory Solid Tumors

ClinicalTrials.gov record

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

NCT04482309 · ACTIVE NOT RECRUITING · phase2

Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2...

ClinicalTrials.gov record

REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

NCT04526106 · COMPLETED · phase1, phase2

FGFR2 Amplification, FGFR2 Gene Mutation, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Translocation, FGFR2 Gene Activation, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma,...

ClinicalTrials.gov record

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

NCT04589845 · ACTIVE NOT RECRUITING · phase2

Solid Tumors

ClinicalTrials.gov record

Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer

NCT04744831 · COMPLETED · phase2

Advanced Colorectal Cancer

ClinicalTrials.gov record

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

NCT04775485 · RECRUITING · phase2

Low-grade Glioma, Advanced Solid Tumor

ClinicalTrials.gov record

A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

NCT05118789 · RECRUITING · phase1, phase2

Locally Advanced Solid Tumor, Metastatic Solid Tumor

ClinicalTrials.gov record

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

NCT05429502 · TERMINATED · phase1

Neuroblastoma

ClinicalTrials.gov record

Antineoplaston Therapy in Treating Children With Rhabdoid Tumor of the Central Nervous System

NCT00003469 · TERMINATED · phase2

Rhabdoid Neoplasm of CNS

ClinicalTrials.gov record

Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia

NCT00003702 · COMPLETED · phase3

Good Prognosis Metastatic Gestational Trophoblastic Tumor, Hydatidiform Mole, Non-Metastatic Gestational Trophoblastic Tumor, Uterine Corpus Choriocarcinoma

ClinicalTrials.gov record

Paclitaxel in Treating Patients With Ovarian Stromal Cancer

NCT00006227 · COMPLETED · phase2

Adult Type Ovarian Granulosa Cell Tumor, Ovarian Gynandroblastoma, Ovarian Sertoli-Leydig Cell Tumor, Ovarian Sex Cord Tumor With Annular Tubules, Ovarian Steroid Cell Tumor

ClinicalTrials.gov record

Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma

NCT00282087 · COMPLETED · phase2

Leiomyosarcoma, Uterine Neoplasm

ClinicalTrials.gov record

Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma

NCT00414076 · TERMINATED · phase2

Leiomyosarcoma, Uterine Neoplasm

ClinicalTrials.gov record

Tumor Necrosis Factor Decreases Vitamin D Dependant Calcium Absorption

NCT00427804 · COMPLETED · na

Rheumatoid Arthritis, Crohn's Disease

ClinicalTrials.gov record

Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath

NCT00578942 · COMPLETED · phase2

Lymphoma, Myeloma, Leukemia, Myelodysplasia, Solid Tumors

ClinicalTrials.gov record

Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath

NCT00580034 · COMPLETED · phase2

Lymphoma, Myeloma, Leukemia, Myelodysplasia, Solid Tumors

ClinicalTrials.gov record

Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)

NCT00700336 · COMPLETED · phase1, phase2

Malignant Pleural Mesothelioma, Solid Tumors

ClinicalTrials.gov record

Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary

NCT00748657 · COMPLETED · phase2

Malignant Ovarian Epithelial Tumor, Ovarian Granulosa Cell Tumor, Ovarian Gynandroblastoma, Ovarian Sertoli-Leydig Cell Tumor, Ovarian Sex Cord Tumor With Annular Tubules,...

ClinicalTrials.gov record

Anderson Circulating Tumor Cell Burden (CTCB) Study

NCT00819832 · TERMINATED · phase4

Cancer, Spinal Disease, Vertebral Compression Fractures

ClinicalTrials.gov record

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

NCT00940225 · COMPLETED · phase2

Solid Tumors, Cancer

ClinicalTrials.gov record

Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors

NCT01042522 · UNKNOWN · phase2

Ovarian Granulosa Cell Tumor, Ovarian Gynandroblastoma, Ovarian Sertoli-Leydig Cell Tumor, Ovarian Sex Cord Tumor With Annular Tubules, Ovarian Sex Cord-Stromal Tumor, Ovarian...

ClinicalTrials.gov record

An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols

NCT01178411 · COMPLETED · phase1, phase2

Advanced Solid Tumors

ClinicalTrials.gov record

Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Participants With Solid Tumors

NCT01190644 · TERMINATED · phase2

Solid Tumors

ClinicalTrials.gov record

A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors

NCT01248949 · COMPLETED · phase1

Advanced Solid Tumors, Advanced Recurrent Ovarian Tumors

ClinicalTrials.gov record

Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia

NCT01535053 · COMPLETED · phase3

Choriocarcinoma, FIGO Stage I Gestational Trophoblastic Tumor, FIGO Stage II Gestational Trophoblastic Tumor, FIGO Stage III Gestational Trophoblastic Tumor, Hydatidiform Mole

ClinicalTrials.gov record

MEK162 for Patients With RAS/RAF/MEK Activated Tumors

NCT01885195 · COMPLETED · phase2

Solid Tumor and Hematologic Malignancies

ClinicalTrials.gov record

Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

NCT02323880 · COMPLETED · phase1

Malignant Glioma, Recurrent Brain Neoplasm, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Glioblastoma, Recurrent Lymphoma, Recurrent Malignant Solid...

ClinicalTrials.gov record

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

NCT02431260 · TERMINATED · phase1, phase2

Solid Tumors and Hematologic Malignancy

ClinicalTrials.gov record

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

NCT02460224 · COMPLETED · phase1, phase2

Advanced Solid Tumors

ClinicalTrials.gov record

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

NCT02554812 · TERMINATED · phase1, phase2

Advanced Cancer

ClinicalTrials.gov record

Study of INCB053914 in Subjects With Advanced Malignancies

NCT02587598 · TERMINATED · phase1, phase2

Solid Tumors

ClinicalTrials.gov record

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

NCT02663518 · TERMINATED · phase1

Hematologic Malignancies, Solid Tumor

ClinicalTrials.gov record

Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)

NCT02664961 · TERMINATED · phase2

Gestational Trophoblastic Neoplasia, Choriocarcinoma, Placental Site Trophoblastic Tumor, Epithelioid Trophoblastic Tumor

ClinicalTrials.gov record

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

NCT02711137 · TERMINATED · phase1, phase2

Solid Tumors

ClinicalTrials.gov record

Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

NCT02717507 · COMPLETED · phase2

Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm

ClinicalTrials.gov record

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

NCT02780804 · COMPLETED · phase1

Brain Stem Neoplasm, Pineal Region Neoplasm, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Recurrent Visual Pathway...

ClinicalTrials.gov record

A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)

NCT03085914 · COMPLETED · phase1, phase2

Solid Tumor

ClinicalTrials.gov record

Yttrium-90 (Y90) Glass Microspheres PET/CT in Imaging Patients With Liver Tumors

NCT03109262 · COMPLETED · na

Primary Malignant Liver Neoplasm

ClinicalTrials.gov record

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

NCT03239145 · COMPLETED · phase1

Advanced Solid Tumor

ClinicalTrials.gov record

Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma

NCT03323034 · COMPLETED · phase1

Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory...

ClinicalTrials.gov record

A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors

NCT03361228 · TERMINATED · phase1, phase2

Solid Tumors

ClinicalTrials.gov record

A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

NCT03601897 · TERMINATED · phase1, phase2

Locally Advanced or Metastatic Solid Tumor

ClinicalTrials.gov record

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

NCT03717415 · TERMINATED · phase1, phase2

Locally Advanced or Metastatic Solid Tumor

ClinicalTrials.gov record

A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies

NCT03926143 · TERMINATED · phase2

Solid Tumors

ClinicalTrials.gov record

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

NCT03989115 · COMPLETED · phase1, phase2

Solid Tumor

ClinicalTrials.gov record

Software-Aided Imaging (Morfeus) for Confirming Tumor Coverage With Ablation in Patients With Liver Tumors, the COVER-ALL Study

NCT04083378 · ACTIVE NOT RECRUITING · phase2

Malignant Liver Neoplasm

ClinicalTrials.gov record

A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

NCT04148937 · COMPLETED · phase1

Advanced Cancer

ClinicalTrials.gov record

A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

NCT04171700 · TERMINATED · phase2

Solid Tumor

ClinicalTrials.gov record

A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.

NCT04209465 · TERMINATED · phase1

Solid Tumor

ClinicalTrials.gov record

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

NCT04306900 · COMPLETED · phase1

Solid Tumor, Adult

ClinicalTrials.gov record

Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery

NCT04420689 · COMPLETED · phase1, phase2

Parotid Neoplasm, Thyroid Neoplasms, Head and Neck Neoplasms, Surgery, Nerve Injury, Imaging

ClinicalTrials.gov record

KZR-261 in Subjects With Advanced Solid Malignancies

NCT05047536 · TERMINATED · phase1

Advanced/Metastatic Solid Tumor

ClinicalTrials.gov record

A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors

NCT05949632 · TERMINATED · phase1, phase2

Advanced Solid Tumors

ClinicalTrials.gov record

A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

NCT06024174 · TERMINATED · phase1, phase2

Advanced Solid Tumors

ClinicalTrials.gov record

A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

NCT06039384 · TERMINATED · phase1

Advanced Solid Tumors

ClinicalTrials.gov record

Disease and treatment settings

Adenoma

Disease and treatment setting

Adenoma

Adrenal Cortical Adenoma

Disease and treatment setting

Adrenal Cortical Adenoma

Adult Leiomyosarcoma

Disease and treatment setting

Adult Leiomyosarcoma

Adult Liposarcoma

Disease and treatment setting

Adult Liposarcoma

Adult Malignant Peripheral Nerve Sheath Tumor

Disease and treatment setting

Adult Malignant Peripheral Nerve Sheath Tumor

Adult Pineocytoma

Disease and treatment setting

Adult Pineocytoma

Adult Teratoma

Disease and treatment setting

Adult Teratoma

Angiomatoid Fibrous Histiocytoma

Disease and treatment setting

Angiomatoid Fibrous Histiocytoma

Atypical Fibroxanthoma

Disease and treatment setting

Atypical Fibroxanthoma

B-Cell Neoplasm

Disease and treatment setting

B-Cell Neoplasm

Brenner Tumor

Disease and treatment setting

Brenner Tumor

Carcinoma In Situ

Disease and treatment setting

Carcinoma In Situ

Carcinosarcoma

Disease and treatment setting

Carcinosarcoma

Childhood Anaplastic Oligodendroglioma

Disease and treatment setting

Childhood Anaplastic Oligodendroglioma

Chondrosarcoma

Disease and treatment setting

Chondrosarcoma

Choriocarcinoma

Disease and treatment setting

Choriocarcinoma

CISplatin: metastatic Ovarian Tumors

Disease and treatment setting

Cisplatin Injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin Injection therapy.

Clear Cell Adenocarcinoma

Disease and treatment setting

Clear Cell Adenocarcinoma

Condyloma Acuminatum

Disease and treatment setting

Condyloma Acuminatum

Dermatofibrosarcoma Protuberans

Disease and treatment setting

Dermatofibrosarcoma Protuberans

Desmoid Fibromatosis

Disease and treatment setting

Desmoid Fibromatosis

Endocrine Carcinoma

Disease and treatment setting

Endocrine Carcinoma

Endometrioid Adenocarcinoma

Disease and treatment setting

Endometrioid Adenocarcinoma

Fibrohistiocytic Neoplasm

Disease and treatment setting

Fibrohistiocytic Neoplasm

FYARRO: unresectable metastatic PEComa

Disease and treatment setting

FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

Gastroesophageal Junction Carcinoma

Disease and treatment setting

Gastroesophageal Junction Carcinoma

Gestational Trophoblastic Tumor

Disease and treatment setting

Gestational Trophoblastic Tumor

Head and Neck Neoplasm

Disease and treatment setting

Head and Neck Neoplasm

Histiocytoma

Disease and treatment setting

Histiocytoma

IMFINZI: metastatic Biliary tract cancer

Disease and treatment setting

1.3 Biliary Tract Cancers IMFINZI, in combination with gemcitabine and cisplatin, is indicated for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC).

Intermediate Grade Lung Neuroendocrine Neoplasm

Disease and treatment setting

Intermediate Grade Lung Neuroendocrine Neoplasm

Intestinal Neoplasm

Disease and treatment setting

Intestinal Neoplasm

Juvenile Xanthogranuloma

Disease and treatment setting

Juvenile Xanthogranuloma

KEYTRUDA QLEX: unresectable metastatic Biliary tract cancer

Disease and treatment setting

1.12 Biliary Tract Cancer KEYTRUDA QLEX, in combination with gemcitabine and cisplatin, is indicated for the treatment of adult patients with locally advanced unresectable or metastatic biliary tract cancer (BTC).

KEYTRUDA: unresectable metastatic Biliary tract cancer

Disease and treatment setting

1.14 Biliary Tract Cancer KEYTRUDA, in combination with gemcitabine and cisplatin, is indicated for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC).

Kidney Carcinoma

Disease and treatment setting

Kidney Carcinoma

Kidney Neoplasm

Disease and treatment setting

Kidney Neoplasm

Leiomyosarcoma

Disease and treatment setting

Leiomyosarcoma

Light Chain Deposition Disease

Disease and treatment setting

Light Chain Deposition Disease

Liposarcoma

Disease and treatment setting

Liposarcoma

Liquid Tumor

Disease and treatment setting

Liquid Tumor

Liver Neoplasm

Disease and treatment setting

Liver Neoplasm

Low Grade Lung Neuroendocrine Neoplasm

Disease and treatment setting

Low Grade Lung Neuroendocrine Neoplasm

Lung Neoplasm

Disease and treatment setting

Lung Neoplasm

Malignant Abdominal Neoplasm

Disease and treatment setting

Malignant Abdominal Neoplasm

Malignant Adult Hemangiopericytoma

Disease and treatment setting

Malignant Adult Hemangiopericytoma

Malignant Ampulla of Vater Neoplasm

Disease and treatment setting

Malignant Ampulla of Vater Neoplasm

Malignant Biliary Tract Neoplasm

Disease and treatment setting

Malignant Biliary Tract Neoplasm

Malignant Bone Neoplasm

Disease and treatment setting

Malignant Bone Neoplasm

Malignant Endocrine Neoplasm

Disease and treatment setting

Malignant Endocrine Neoplasm

Malignant Head and Neck Neoplasm

Disease and treatment setting

Malignant Head and Neck Neoplasm

Malignant Kidney Neoplasm

Disease and treatment setting

Malignant Kidney Neoplasm

Malignant Lung Neoplasm

Disease and treatment setting

Malignant Lung Neoplasm

Malignant Pelvic Neoplasm

Disease and treatment setting

Malignant Pelvic Neoplasm

Malignant Peripheral Nerve Sheath Tumor

Disease and treatment setting

Malignant Peripheral Nerve Sheath Tumor

Malignant Peritoneal Neoplasm

Disease and treatment setting

Malignant Peritoneal Neoplasm

Malignant Prostate Neoplasm

Disease and treatment setting

Malignant Prostate Neoplasm

Malignant Ureter Neoplasm

Disease and treatment setting

Malignant Ureter Neoplasm

Malignant Uterine Corpus Neoplasm

Disease and treatment setting

Malignant Uterine Corpus Neoplasm

Malignant Uterine Neoplasm

Disease and treatment setting

Malignant Uterine Neoplasm

Mesenchymal Chondrosarcoma

Disease and treatment setting

Mesenchymal Chondrosarcoma

Micropapillary Serous Carcinoma

Disease and treatment setting

Micropapillary Serous Carcinoma

Mixed Mesodermal (Mullerian) Tumor

Disease and treatment setting

Mixed Mesodermal (Mullerian) Tumor

Monoclonal Gammopathy of Undetermined Significance

Disease and treatment setting

Monoclonal Gammopathy of Undetermined Significance

Mucinous Adenocarcinoma

Disease and treatment setting

Mucinous Adenocarcinoma

Myeloid Neoplasm

Disease and treatment setting

Myeloid Neoplasm

Myoma

Disease and treatment setting

Myoma

Nerve Sheath Neoplasm

Disease and treatment setting

Nerve Sheath Neoplasm

Neuroendocrine Neoplasm

Disease and treatment setting

Neuroendocrine Neoplasm

Oligoastrocytoma

Disease and treatment setting

Oligoastrocytoma

Ovarian Neoplasm

Disease and treatment setting

Ovarian Neoplasm

Pancreatic Intraductal Papillary Mucinous Neoplasm

Disease and treatment setting

Pancreatic Intraductal Papillary Mucinous Neoplasm

Papillary Adenocarcinoma

Disease and treatment setting

Papillary Adenocarcinoma

Papilloma

Disease and treatment setting

Papilloma

PEComa

Disease and treatment setting

PEComa

Pericytic Neoplasm

Disease and treatment setting

Pericytic Neoplasm

Peritoneal Neoplasm

Disease and treatment setting

Peritoneal Neoplasm

Pleomorphic Xanthoastrocytoma

Disease and treatment setting

Pleomorphic Xanthoastrocytoma

Poor Prognosis Metastatic Gestational Trophoblastic Tumor

Disease and treatment setting

Poor Prognosis Metastatic Gestational Trophoblastic Tumor

Primitive Neuroectodermal Tumor

Disease and treatment setting

Primitive Neuroectodermal Tumor

Recurrent Childhood Anaplastic Oligoastrocytoma

Disease and treatment setting

Recurrent Childhood Anaplastic Oligoastrocytoma

Recurrent Childhood Anaplastic Oligodendroglioma

Disease and treatment setting

Recurrent Childhood Anaplastic Oligodendroglioma

Recurrent Childhood Gliomatosis Cerebri

Disease and treatment setting

Recurrent Childhood Gliomatosis Cerebri

Recurrent Childhood Oligoastrocytoma

Disease and treatment setting

Recurrent Childhood Oligoastrocytoma

Recurrent Childhood Oligodendroglioma

Disease and treatment setting

Recurrent Childhood Oligodendroglioma

Recurrent Histiocytic and Dendritic Cell Neoplasm

Disease and treatment setting

Recurrent Histiocytic and Dendritic Cell Neoplasm

Recurrent Rhabdoid Tumor

Disease and treatment setting

Recurrent Rhabdoid Tumor

Refractory Histiocytic and Dendritic Cell Neoplasm

Disease and treatment setting

Refractory Histiocytic and Dendritic Cell Neoplasm

Refractory Peripheral Primitive Neuroectodermal Tumor

Disease and treatment setting

Refractory Peripheral Primitive Neuroectodermal Tumor

Refractory Rhabdoid Tumor

Disease and treatment setting

Refractory Rhabdoid Tumor

Rhabdoid Tumor

Disease and treatment setting

Rhabdoid Tumor

Squamous Cell Neoplasm

Disease and treatment setting

Squamous Cell Neoplasm

Teratoma

Disease and treatment setting

Teratoma

Thoracic Neoplasm

Disease and treatment setting

Thoracic Neoplasm

Ureter Carcinoma

Disease and treatment setting

Ureter Carcinoma

Ureter Neoplasm

Disease and treatment setting

Ureter Neoplasm

Urethra Neoplasm

Disease and treatment setting

Urethra Neoplasm

Uterine Carcinosarcoma

Disease and treatment setting

Uterine Carcinosarcoma

Uterine Neoplasm

Disease and treatment setting

Uterine Neoplasm

Valstar: refractory Carcinoma In Situ

Disease and treatment setting

VALSTAR is an anthracycline topoisomerase inhibitor indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable...

Ziihera: unresectable metastatic Biliary tract cancer with HER2 positive

Disease and treatment setting

Treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test

Drug labels

ABRILADA

Label date 2026-05-06

ABRILADA is a tumor necrosis factor (TNF) blocker indicated for: • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...

DailyMed label

ABRILADA

Label date 2026-08-07

ABRILADA is a tumor necrosis factor (TNF) blocker indicated for: • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...

DailyMed label

ABRILADA

Label date 2026-06-18

ABRILADA is a tumor necrosis factor (TNF) blocker indicated for: • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...

DailyMed label

Adalimumab

Label date 2026-01-12

Adalimumab-fkjp is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving...

DailyMed label

Adalimumab

Label date 2026-07-08

Adalimumab-aaty is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients...

DailyMed label

Adalimumab

Label date 2025-10-21

Adalimumab-adaz is a tumor necrosis factor (TNF)-blocker indicated for: • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients...

DailyMed label

Adalimumab-aacf

Label date 2026-01-08

Adalimumab-aacf is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving...

DailyMed label

Adalimumab-adbm

Label date 2025-11-12

Adalimumab-adbm is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients...

DailyMed label

Adalimumab-adbm

Label date 2024-11-12

Adalimumab-adbm is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients...

DailyMed label

Adalimumab-bwwd

Label date 2025-10-17

Adalimumab-bwwd is a tumor necrosis factor (TNF) blocker indicated for • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients...

DailyMed label

Adalimumab-ryvk

Label date 2026-03-03

Adalimumab-ryvk is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients...

DailyMed label

Adalimumab-ryvk

Label date 2026-01-19

Adalimumab-ryvk is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients...

DailyMed label

Adalimumab-ryvk

Label date 2025-12-31

Adalimumab-ryvk is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients...

DailyMed label

Allopurinol

Label date 2026-05-21

1 INDICATIONS & USAGE Allopurinol tablet is indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management...

DailyMed label

Allopurinol

Label date 2025-02-05

1 INDICATIONS & USAGE Allopurinol tablet is indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management...

DailyMed label

Allopurinol

Label date 2024-04-01

Allopurinol Tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and...

DailyMed label

Aloprim

Label date 2022-02-18

ALOPRIM is indicated for the management of adult and pediatric patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot...

DailyMed label

AMJEVITA

Label date 2026-07-13

AMJEVITA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...

DailyMed label

AMJEVITA

Label date 2026-06-25

AMJEVITA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...

DailyMed label

AMJEVITA

Label date 2026-06-25

AMJEVITA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...

DailyMed label

AVSOLA

Label date 2026-07-22

AVSOLA is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease : reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an...

DailyMed label

Bromocriptine Mesylate

Label date 2026-06-12

INDICATIONS & USAGE Hyperprolactinemia-Associated Dysfunctions Bromocriptine mesylate is indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or...

DailyMed label

Cimzia

Label date 2026-02-24

CIMZIA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate...

DailyMed label

CRYSVITA

Label date 2026-04-22

CRYSVITA is a fibroblast growth factor 23 (FGF23) blocking antibody indicated for: The treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older. ( 1.1 ) The treatment of FGF23-related...

DailyMed label

Cyltezo

Label date 2026-05-22

CYLTEZO is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...

DailyMed label

DECNUPAZ

Label date 2026-05-27

1. INDICATIONS AND USAGE DECNUPAZ is indicated for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). DECNUPAZ is a CD123-directed antibody and alkylating agent conjugate indicated for the...

DailyMed label

Elitek

Label date 2026-07-30

Elitek is indicated for the initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and...

DailyMed label

Elzonris

Label date 2024-12-09

ELZONRIS is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older. ELZONRIS is a CD123-directed cytotoxin indicated for the treatment of blastic...

DailyMed label

ENBREL

Label date 2026-05-11

Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with: Rheumatoid Arthritis (RA) ( 1.1 ) Psoriatic Arthritis (PsA) ( 1.3 ) Ankylosing Spondylitis (AS) ( 1.4 ) Plaque Psoriasis (PsO) ( 1.5 )...

DailyMed label

FYARRO

Label date 2026-05-19

FYARRO ® is indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO is an mTOR inhibitor indicated for the treatment of adult patients...

DailyMed label

HADLIMA

Label date 2023-10-02

HADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical...

DailyMed label

HADLIMA

Label date 2026-05-14

HADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...

DailyMed label

HADLIMA

Label date 2023-10-23

HADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical...

DailyMed label

HULIO

Label date 2025-02-06

HULIO is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical...

DailyMed label

Humira

Label date 2025-12-23

HUMIRA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...

DailyMed label

Humira

Label date 2025-12-23

HUMIRA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...

DailyMed label

HUMIRA

Label date 2024-05-16

HUMIRA is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA) ( 1.1 ) : reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical...

DailyMed label

HYRIMOZ

Label date 2025-10-17

HYRIMOZ is a tumor necrosis factor (TNF)-blocker indicated for: • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...

DailyMed label

HYRIMOZ

Label date 2025-10-17

HYRIMOZ is a tumor necrosis factor (TNF)-blocker indicated for: • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...

DailyMed label

IDACIO

Label date 2024-10-15

IDACIO is a tumor necrosis factor (TNF) blocker indicated for: • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical...

DailyMed label

Idacio

Label date 2026-01-30

IDACIO is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical...

DailyMed label

Ilaris

Label date 2026-06-08

ILARIS is an interleukin-1β blocker indicated for the treatment of: • Periodic Fever Syndromes ( 1.1 ): - Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold...

DailyMed label

INFLECTRA

Label date 2026-07-28

INFLECTRA is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease ( 1.1 ): • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who...

DailyMed label

INFLIXIMAB

Label date 2026-02-11

Infliximab is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease : reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had...

DailyMed label

Kineret

Label date 2026-04-03

KINERET is an interleukin-1 receptor antagonist indicated for: Rheumatoid Arthritis (RA) Reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients...

DailyMed label

Olumiant

Label date 2026-06-30

OLUMIANT ® is a Janus kinase (JAK) inhibitor indicated for: the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. ( 1.1 ) Limitations of...

DailyMed label

PEDMARK

Label date 2025-10-27

PEDMARK is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors. Limitations of Use The safety and efficacy of PEDMARK have not...

DailyMed label

REMICADE

Label date 2025-06-03

REMICADE is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease : reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an...

DailyMed label

Renflexis

Label date 2026-08-28

RENFLEXIS is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease: reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an...

DailyMed label

Simlandi

Label date 2025-10-31

SIMLANDI is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...

DailyMed label

Simlandi

Label date 2025-10-16

SIMLANDI is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA): Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function...

DailyMed label

Simponi

Label date 2025-10-29

SIMPONI is a tumor necrosis factor (TNF) blocker indicated for the treatment of: adult patients with moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate ( 1.1 ) adult patients with active psoriatic...

DailyMed label

SIMPONI ARIA

Label date 2025-09-09

SIMPONI ARIA is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with moderately to severely active Rheumatoid Arthritis (RA) in combination with methotrexate ( 1.1 ) Active Psoriatic Arthritis (PsA)...

DailyMed label

TICE BCG

Label date 2026-02-20

INDICATIONS AND USAGE TICE ® BCG is indicated for: the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral...

DailyMed label

VITRAKVI

Label date 2026-05-22

VITRAKVI is indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase ( NTRK ) gene fusion without a known acquired resistance mutation, are metastatic or where...

DailyMed label

VITRAKVI

Label date 2018-12-05

VITRAKVI is indicated for the treatment of adult and pediatric patients with solid tumors that: • have a neurotrophic receptor tyrosine kinase ( NTRK ) gene fusion without a known acquired resistance mutation, • are metastatic or where...

DailyMed label

Yuflyma

Label date 2026-07-15

YUFLYMA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...

DailyMed label

YUSIMRY

Label date 2025-10-31

YUSIMRY is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...

DailyMed label

YUSIMRY

Label date 2025-05-16

YUSIMRY is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical...

DailyMed label

ZYMFENTRA

Label date 2026-08-18

ZYMFENTRA is a tumor necrosis factor (TNF) blocker indicated in adults for maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously. ( 1 )...

DailyMed label